At Redoxis, we have a fully equipped lab for work with both primary cells and cell lines. We also hava fully equipped laboratory for post experiment follow up analyses and stand alone immunology assays. We have during the fall further enhanced our capacity for such studies by acquiring an Attune NxT flow cytometer (Thermo Fisher […]
In the 9th of December we will attend the PHARMA OUTSOURCING meeting in Stockholm- This is a new annual international partnering meeting for Investment Managers and R&D professionals in biotech-, pharma-, virtual- and start up companies to meet, network and discuss best practices in pharma outsourcing.
NEURINOX gathers top researchers, patients and industry in an international symposium on innovative concepts for treating neurodegenerative diseases
Neurodegeneration leads to chronic debilitating diseases, including age-related syndromes like Alzheimer’s and Parkinson’s diseases and disorders affecting younger people such as epilepsy and multiple sclerosis. A common disease mechanism in neurodegeneration is inflammation of the brain, also referred to as neuroinflammation. Neurinox, a 5-year international biomedical research project running until the end of 2016, was […]
Attending one of the largest partnering event in Life Science, these days taking place in Stockholm 9-10 September- 2015. This will be an event not only to meet with research partners and Sponsors for Redoxis preclinical models of autoimmunity, but also initiation of discussion with partners for next call to H2020.
Redoxis has been approved by the French authorities “Ministère chargé de l’Enseignement supérieur et de la Recherche” eligible for tax reduction for services performed by Redoxis for French research entities. For further information please contact us at firstname.lastname@example.org or directly to Peter Olofsson, CEO or Malin Hutqvist, CSO.